Recent Updates
Recently added Catalysts
MNPR Positive Sentiment

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Wednesday, September 4, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Monopar Therapeutics Inc. will present at the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9, 2024. CEO Chandler D. Robinson will be presenting, with the webcast starting at 7:00 a.m. ET. The conference will also feature in-person one-on-one meetings from September 9 to 11, 2024, at the Lotte New York Palace. Monopar focuses on developing innovative treatments for cancer patients, including multiple projects in various stages of development.
Price reaction · baseline $2.37 (2024-09-03 close) · hit after-hours · clean, no other MNPR news in the window
day 0 close
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Monopar Therapeutics is participating in a significant investment conference.
  • The company is focused on innovative treatments for cancer patients.
  • The presence of the CEO at the conference suggests strong leadership engagement.
  • The scheduled webcast presents opportunities for remote investors to engage.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+140%
120-day peak, hindsight
Typical move
5.5%
average across 4 past catalysts
Cash runway
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177Lu
Phase 1 · Solid Tumor, Adult

Full Press Release Details

WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 9, 2024 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 9 - 11, 2024.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.
Monopar Therapeutics Inc.
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

Frequently Asked Questions

When will Monopar present at the H.C. Wainwright Conference?

Monopar will present on September 9, 2024, at 7:00 a.m. ET.

Where will the one-on-one meetings be held?

Meetings will take place at the Lotte New York Palace, NY, from September 9-11.

What is the focus of Monopar Therapeutics?

Monopar focuses on innovative cancer treatments, including radiopharmaceuticals.

What are some treatments in Monopar's pipeline?

Their pipeline includes MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac225.

How can I learn more about Monopar?

Visit their website at www.monopartx.com for more information.

ShareAdd on Google
Tags: MNPR Viatris Investor Conferences Healthcare Monopar Therapeutics H.C. Wainwright cancer treatments investment conference
Last updated: Sep 4, 2024

Biotech snapshot

Cash runway
$105M liquidity · $1M/mo burn
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177LuPhase 1
Solid Tumor, Adult →

Catalyst track record

+140%
best trade around MNPR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for MNPR.

See every catalyst's timing & PoA →